|
Symposium
SOT-PBSS Joint Spring Symposium: Immuno-oncology: Opportunities, Therapeutic Approaches, and Safety Considerations
Speakers:
Keith Bahjat (Bristol-Myers Squibb), Haleh Saber (FDA), Sunjay Sethi (University of California Davis), Henry QX Li (Crown Bioscience), Greg Bannish (Envigo), Rodney Prell (Genentech), Herve Lebrec (Amgen Inc.), Allyson Byrd (Genentech)
Organizers:
Date:
2018-04-27
Time:
8:00-17:00 Pacific Time
Registration fee:
(USD): Regular: $50
Location:
South San Francisco Conference Center (255 South Airport Boulevard, South San Francisco, CA 94080)
Major Sponsor:
Vendor show vendors registered to date:
(1)PHARMout Laboratories
Registration: http://www.PBSS.org
Registration deadline:2018-04-22
(it will close sooner if the seating cap is reached)
About the Topic
Over the past decade, tremendous progress has been made in understanding the interplay between the immune system and cancer. Consequently, cancer immunotherapy (aka immuno-oncology), which is intended to induce or enhance an immune response to the cancer, has had several recent approvals and seen remarkable growth in discovering and developing new and exciting technologies. Many research institutions and pharmaceutical companies have promising research programs which involve novel drug targets on immune cells, or which utilize therapeutic approaches designed to engage the immune system to kill the cancer cells.
This year’s joint symposium between NorCal SOT and PBSS will involve presentations describing the interplay between the immune system and cancer and therapeutic approaches which harness the power of the immune system as a means to treat cancer. There will also be in-depth presentations on safety assessment for new immuno-oncology drugs, including presentations by pharmaceutical safety assessment scientists on several of the leading therapeutic approaches- checkpoint inhibitors, T-cell redirecting therapies and adaptive cell transfer/CAR-T cells, as well as perspectives from an FDA reviewer on the unique challenges with developing cancer immunotherapeutics. In addition, there will be presentations summarizing animal models to support preclinical research, clinical challenges in developing immune therapies and how the microbiome can influence the immune system and thus cancer immunotherapies.
Agenda
Morning Session
7:30 am – 8:30 am Registration & Breakfast
8:30 am – 8:45 am Opening Messages from the NorCal SOT & PBSS Presidents
- Doris Zane, PhD, DABT, Senior Director, Preclinical Development, Intarcia Therapeutics, Inc.
- Shichang Miao,PhD, Vice President, Preclinical Development and Clinical DMPK, ChemoCentryx Inc.
8:45 am – 9:25 am Presentation 1: A Brief History of Immunotherapy,
- Keith Bahjat, PhD, Director, Bristol-Myers Squibb
9:25 am – 10:10 am Presentation 2: Immune-Oncology: Nonclinical Challenges
- Haleh Saber, PhD, Deputy Director, Division of Hematology Oncology Toxicology, FDA
10:10 am – 10:25 am Coffee Break
10:25 am – 10:50 am NorCal Student Award presentation: Influence of Genetic Background onPolychlorinated Biphenyl (PCB) Developmental Neurotoxicity
- Sunjay Sethi, Graduate Student, University of California Davis
10:50 am – 11:30 am Presentation 3: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model
- Henry QX Li, PhD, Senior Vice President, Global Scientific Research and Innovation Division, Crown Bioscience
11:30 am – 12:10 pm Presentation 4: Title TBD (Topic – Preclinical development – animal models for selecting/optimizing drug candidates)
- Greg Bannish, PhD, Vice President, Biopharmaceutical Development, Envigo
12:10 pm – 1:40 pm Lunch Break: Lunch with Experts, Posters
Afternoon Session
1:40 pm – 1:55 pm Chapter Announcements and Acknowledgements
1:55 pm – 2:35 pm Presentation 5: Nonclinical Safety Challenges for Cancer Immunotherapeutics
- Rodney Prell, PhD, DABT, Principal Scientist/Toxicologist, Genentech
2:35 pm – 3:15 pm Presentation 6: Nonclinical Safety Assessment of CARTs: A Multipronged Approach
- Herve Lebrec, PhD, DABT, Scientific Director, Amgen Inc.
3:15 pm – 3:30 pm Coffee Break
3:30 pm – 4:00 pm Presentation 7: Microbiome Research as an Innovative Platform for Biomarker and Drug Discovery
- Allyson Byrd, PhD, Genentech
4:00 pm – 4:05 pm Closing Remarks
4:05 pm – 5:00 pm Reception & Networking
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|